Nod To COVAXIN Trial Via Skin

Hyderabad: The Drugs Controller General of India (DGCI) has given permission to Bharat Biotech to test its COVID-19 vaccine, COVAXIN, by administering it via the skin.


This intradermal vaccine delivery route is less invasive and will require a lesser dosage as well. The inactive virus-based vaccine is also being tested to be delivered in the intramuscular way.

Currently, the indigenously built vaccine is in phase II trials.

Get real time updates directly on you device, subscribe now.

Comments are closed.